{"gene":"BRCC3","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2009,"finding":"BRCC36 (BRCC3) is the catalytic subunit of the BRISC complex and exhibits K63-linked polyubiquitin chain-specific deubiquitinating (DUB) activity; it lacks an active-site cysteine and instead uses a JAMM/MPN+ zinc metalloprotease mechanism. The K63-specific DUB activity is intrinsic to the BRISC complex and does not cleave K6, K11, K29, K48, or alpha-linked chains.","method":"Biochemical fractionation through seven chromatographic steps; fluorometric DUB assays with linkage-specific ubiquitin substrates; NEM/ubiquitin-aldehyde insensitivity tests","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with defined substrates, multiple orthogonal biochemical methods, linkage specificity rigorously demonstrated","pmids":["19214193"],"is_preprint":false},{"year":2007,"finding":"BRCC36 (BRCC3) is a component of the BRCA1-A complex (also containing BRCA1/BARD1, ABRAXAS/CCDC98, RAP80, BRCC45/BRE, MERIT40). BRCC36 associates with ABRAXAS via coiled-coil domains on each protein, and RAP80 contains an Abraxas-interacting region (AIR) required for association of RAP80 with ABRAXAS, BRCA1, and BRCC36. The entire complex is recruited to DNA double-strand break (DSB) foci through RAP80 UIM-domain binding to RNF8/Ubc13-generated K63-linked polyubiquitin chains.","method":"Co-immunoprecipitation; domain mapping; RNAi knockdown of RNF8/Ubc13 with immunofluorescence foci assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and domain mapping, replicated in multiple independent labs","pmids":["18077395"],"is_preprint":false},{"year":2009,"finding":"The RAP80-BRCC36 complex opposes RNF8-Ubc13-dependent ubiquitination at DSBs. BRCC36 knockdown or expression of a DUB-inactive BRCC36 mutant rescued 53BP1 recruitment and γ-H2AX ubiquitination following RNF8 depletion, demonstrating that BRCC36 hydrolase activity counterbalances RNF8 ubiquitin ligase activity to set steady-state ubiquitin levels at DSBs.","method":"siRNA knockdown; DUB-inactive mutant expression; immunofluorescence; ionizing radiation sensitivity assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with catalytic mutant, replicated with multiple approaches, independent lab from PMID:18077395","pmids":["19202061"],"is_preprint":false},{"year":2010,"finding":"BRCC36 exists in two distinct subcellular complexes determined by two scaffold proteins: nuclear ABRAXAS/CCDC98 (within the BRCA1-A complex) and cytoplasmic KIAA0157 (ABRO1, within BRISC). ABRAXAS and KIAA0157 each regulate BRCC36 DUB activity. Reduction of KIAA0157 increases the BRCA1-A complex in the nucleus, indicating the two complexes are in dynamic balance. BRCC36 reduces K63-linked ubiquitin chains at chromatin and deubiquitinates diubiquitinated histone H2A.","method":"Co-immunoprecipitation; subcellular fractionation; siRNA knockdown; in vitro DUB assays with K63-linked diubiquitin-H2A substrate","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro DUB assay on defined substrate plus Co-IP, fractionation, and RNAi with functional consequence, single lab but multiple orthogonal methods","pmids":["20656690"],"is_preprint":false},{"year":2011,"finding":"Both the nuclear BRCA1-A (ABRAXAS-containing) and cytoplasmic BRISC (ABRO1-containing) complexes share the common subunits BRE and NBA1/MERIT40. NBA1 and BRE interact through a C-terminal conserved motif of NBA1 and the C-terminal UEV domain of BRE; this interaction is essential for maintaining the integrity of both complexes and for cellular resistance to ionizing radiation and BRCA1 recruitment to DSBs.","method":"Co-immunoprecipitation; domain deletion/mutation mapping; siRNA knockdown; clonogenic survival assays; immunofluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, functional validation by clonogenic assay, multiple orthogonal methods single lab","pmids":["21282113"],"is_preprint":false},{"year":2012,"finding":"BRCC3 (BRCC36) deubiquitinates NLRP3 and acts as a critical positive regulator of NLRP3 inflammasome activation. NLRP3 is a substrate of the cytosolic BRISC complex containing BRCC3. Pharmacological and siRNA-mediated inhibition of BRCC3 DUB activity suppresses NLRP3 inflammasome activation.","method":"Pharmacological DUB inhibition; siRNA knockdown; ubiquitination assays; caspase-1 and IL-1β activity assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (pharmacological + genetic), substrate identification, widely replicated by independent labs","pmids":["23246432"],"is_preprint":false},{"year":2006,"finding":"BRCC36 (BRCC3) regulates BRCA1 activation in response to DNA damage: knockdown of BRCC36 disrupts ionizing radiation-induced BRCA1 phosphorylation and prevents formation of BRCA1 nuclear foci at DSBs, sensitizing breast cancer cells to IR-induced apoptosis. BRCC36 regulates ubiquitin E3 ligase activity of the BRCC complex.","method":"siRNA knockdown in MCF-7, ZR-75-1, T47D cells; immunoblot; immunofluorescence of BRCA1 and γ-H2AX foci; apoptosis assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined cellular phenotype (foci, phosphorylation, apoptosis), single lab, multiple cell lines","pmids":["16707425"],"is_preprint":false},{"year":2011,"finding":"Loss of BRCC3 function in zebrafish (brcc3 morphants) causes angiogenesis defects that are rescued by endothelium-specific expression of brcc3, establishing BRCC3 as an essential regulator of angiogenesis in vivo.","method":"Morpholino knockdown in zebrafish; rescue by endothelium-specific BRCC3 expression; vascular imaging","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiment in zebrafish ortholog with tissue-specific complementation, single lab","pmids":["21596366"],"is_preprint":false},{"year":2015,"finding":"Structural characterization of the BRCC36-KIAA0157 (ABRO1) heterodimer reveals BRCC36 is activated by contacts with the pseudo-DUB KIAA0157 (MPN− domain). An inactive BRCC36 homodimer exists; heterodimerization with KIAA0157 switches BRCC36 to an active conformation. Furthermore, a higher-order dimer-of-heterodimers ('super-dimer') assembly is required for full DUB activity and for interactions with targeting proteins SHMT2 and RAP80.","method":"X-ray crystallography; in vitro DUB activity assays; mutagenesis of interface residues; size-exclusion chromatography/analytical ultracentrifugation; pulldown assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus in vitro reconstitution, mutagenesis, and functional validation in single rigorous study","pmids":["26344097"],"is_preprint":false},{"year":2016,"finding":"BRCC36 DUB activity within the BRCA1-A complex limits DSB end resection and DNA repair. Inactivation of BRCC36 DUB (via RNAi or CRISPR editing) attenuated BRCA1-A complex accumulation at DSBs and led to unrestrained DSB end resection and hyperactive DNA repair, while the structural integrity of the complex was maintained.","method":"RNAi; CRISPR/Cas9 genome editing; catalytic mutant expression; end resection assays; BRCA1-A foci quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — catalytic mutant plus CRISPR KO with mechanistic endpoint (resection), two orthogonal genetic approaches","pmids":["27288411"],"is_preprint":false},{"year":2016,"finding":"The BRISC complex (ABRO1/BRCC36) removes K63-linked ubiquitin chains from tankyrase 1 in G1 phase, while RNF8 adds K63-linked ubiquitin chains in late S/G2. This ubiquitination/deubiquitination cycle controls tankyrase 1 stabilization, telomere association, and resolution of sister telomere cohesion in a cell cycle-regulated manner.","method":"Co-immunoprecipitation; ubiquitination assays; cell cycle synchronization; telomere FISH; siRNA knockdown of ABRO1/BRCC36","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — substrate identification with cell-cycle-staged ubiquitination assays, genetic epistasis, multiple orthogonal methods","pmids":["27993934"],"is_preprint":false},{"year":2019,"finding":"Crystal/cryo-EM structures of the BRCA1-A and BRISC complexes reveal: (1) In BRCA1-A, ABRAXAS integrates RAP80 and provides a high-affinity BRCA1-binding site that sequesters BRCA1 away from DSBs. (2) In BRISC, ABRO1 binds the metabolic enzyme SHMT2α, which in this context prevents BRCC36 from binding and cleaving ubiquitin chains (inhibitory regulation). Different adaptor subunits thus confer diversified targeting and regulatory functions on the same BRCC36 catalytic subunit.","method":"Cryo-EM and X-ray crystallography; in vitro DUB activity assays; binding assays; mutagenesis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution structures of both complexes combined with in vitro functional validation and mutagenesis in single rigorous study","pmids":["31253574"],"is_preprint":false},{"year":2018,"finding":"SHMT2 acts as a regulatory adaptor in the BRISC complex: SHMT2 and BRCC36 (via BRISC) regulate HIV-1 Tat K63-ubiquitylation. Knockdown of SHMT1/2 or BRCC36 strongly increased K63-Ub-dependent autophagic destruction of Tat; point mutation of multiple lysines in Tat or knockdown of BRCC36/SHMT1,2 prevented JIB-04-induced Tat destruction.","method":"Proximity proteomics (DiffPOP); mass spectrometry; siRNA knockdown; Tat ubiquitination assays; autophagy flux assays; site-directed mutagenesis of Tat lysines","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (proteomics, mutagenesis, genetic KD) in single lab","pmids":["29791506"],"is_preprint":false},{"year":2019,"finding":"Vitamin D receptor (VDR) physically binds NLRP3 and blocks the association of NLRP3 with BRCC3, thereby preventing BRCC3-mediated deubiquitination and subsequent NLRP3 activation. VDR thus acts as a negative regulator of NLRP3 by competing with BRCC3 for NLRP3 binding.","method":"Co-immunoprecipitation; ubiquitination assays; VDR knockout mice; IL-1β/caspase-1 activation assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP demonstrating competitive binding, in vivo KO validation, single lab with multiple methods","pmids":["31866999"],"is_preprint":false},{"year":2020,"finding":"ABRO1 stabilizes BRCC3 protein by competing with the HECT-type E3 ubiquitin ligase WWP2 for binding to BRCC3, thereby preventing WWP2-mediated K48-linked ubiquitination and proteasomal degradation of BRCC3. WWP2 overexpression in macrophages inhibits NLRP3 inflammasome activation by reducing BRCC3 levels.","method":"Co-immunoprecipitation; ubiquitination assays; cycloheximide chase; siRNA/lentiviral overexpression; caspase-1 and IL-1β assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (competition Co-IP, degradation assays, functional readout) in single lab","pmids":["33107021"],"is_preprint":false},{"year":2021,"finding":"BRCC36 (BRCC3) specifically associates with FLT3-ITD (but not wild-type FLT3 or FLT3-TKD) through K63-linked polyubiquitination at K609 of the ITD mutant. BRCC36 knockdown decreases STAT5 phosphorylation and cell proliferation in FLT3-ITD AML cells.","method":"Proximity labeling (TurboID); K63-ubiquitination assays; site-directed mutagenesis (K609R); siRNA knockdown; phospho-STAT5 immunoblot; cell proliferation assays","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity labeling plus mutagenesis of ubiquitination site and functional validation, single lab","pmids":["38288901"],"is_preprint":false},{"year":2021,"finding":"HSV-1-encoded ICP0 induces K48-linked polyubiquitination and proteasomal degradation of BRCC36, leading to downmodulation of IFN-I receptor IFNAR1 and suppression of the host type I interferon antiviral response.","method":"Co-immunoprecipitation; ubiquitination assays; viral infection time-courses; immunoblot; IFNAR1 surface level measurement","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — viral protein-host DUB interaction identified by Co-IP with mechanistic downstream readout (IFNAR1), single lab","pmids":["33857816"],"is_preprint":false},{"year":2020,"finding":"BRCC36 maintains STAT1 protein stability noncatalytically by recruiting USP13 to form a complex that antagonizes Smurf1-mediated STAT1 degradation. BRCC36 deficiency causes rapid STAT1 downregulation during viral infection, impairing antiviral immunity in vivo.","method":"Co-immunoprecipitation; STAT1 stability assays; viral challenge in BRCC36-deficient mice; USP13/Smurf1 epistasis experiments","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complex identification by Co-IP with in vivo validation and genetic epistasis, single lab","pmids":["32673428"],"is_preprint":false},{"year":2023,"finding":"In TET2-deficient macrophages, increased JNK1 signaling (due to hypermethylation and decreased expression of the phosphatase DUSP10) promotes BRCC3-mediated NLRP3 deubiquitylation and inflammasome activation, accelerating atherosclerosis. The BRCC3 inhibitor holomycin or hematopoietic deficiency of ABRO1 (essential BRISC scaffolding protein) reversed accelerated atherosclerosis and NETosis in Tet2 CH mice.","method":"Cholesterol-loaded TET2-deficient macrophages (murine and human ESC-derived isogenic); JNK1 phosphorylation assays; NLRP3 ubiquitylation assays; Tet2 CH mouse atherosclerosis model; ABRO1 hematopoietic KO; holomycin pharmacological inhibition","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — pathway epistasis (JNK1→BRCC3→NLRP3), pharmacological and genetic inhibition, both murine and human models, independent validation of ABRO1 scaffolding requirement","pmids":["37781816"],"is_preprint":false},{"year":2019,"finding":"BRCC3 mutations in AML with t(8;21) abrogate its DUB activity on IFNAR1, resulting in impaired interferon response, and also diminish inflammasome activity. BRCC3 inactivation by CRISPR/Cas9 in t(8;21) AML cell lines improved proliferation and, combined with AML1-ETO, induced unlimited self-renewal of mouse hematopoietic progenitors.","method":"CRISPR/Cas9 inactivation; DUB activity assays on IFNAR1 substrate; interferon response assays; colony-forming assays; cytokine profiling","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with defined biochemical endpoint (DUB activity on IFNAR1) and multiple functional readouts, single lab","pmids":["31576005"],"is_preprint":false},{"year":2024,"finding":"BRCC36 deubiquitinates HMGCR in a DUB-activity-dependent manner, stabilizing HMGCR and suppressing ferroptosis while promoting pyroptosis in hepatocellular carcinoma cells.","method":"Co-immunoprecipitation; ubiquitination assays; DUB-inactive mutant; cell death assays (ferroptosis/pyroptosis markers); in vivo xenograft model with thiolutin (BRCC36 inhibitor)","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identified by Co-IP and ubiquitination assay with catalytic mutant control, single lab","pmids":["38178583"],"is_preprint":false},{"year":2024,"finding":"BRCC3 deubiquitinates ALK2 at Lys-472 and Lys-475 (K63-linked), activating receptor-regulated Smad1/5/9 and transcriptional activation of BMP-regulated PPARγ, p53, and Id1. BRCC3 also attenuates TGF-β signaling by downregulating TGF-β expression and inhibiting Smad3 phosphorylation. Smooth muscle cell-specific BRCC3 transgenic mice are protected from experimental pulmonary hypertension, while Brcc3−/− mice show increased susceptibility.","method":"Bioinformatic ubiquitination site prediction; site-directed mutagenesis (K472/475R ALK2); Co-immunoprecipitation; ubiquitination assays; SM22α-BRCC3-Tg and Brcc3−/− mouse models; pulmonary hemodynamics","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — site-specific mutagenesis confirming ubiquitination sites, gain-of-function and loss-of-function mouse models, multiple downstream pathway readouts","pmids":["38557054"],"is_preprint":false},{"year":2022,"finding":"BRCC36 binds β-catenin and inhibits its phosphorylation; BRCC36 overexpression reduces phosphorylated β-catenin levels in the nucleus and calcium deposition in VSMCs, negatively regulating the Wnt/β-catenin pathway to prevent vascular calcification.","method":"Co-immunoprecipitation; immunofluorescence; Alizarin red staining; calcium content assays; overexpression/knockdown in VSMCs and CKD mouse model","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP of interaction with functional outcome in two model systems, single lab, β-catenin deubiquitination mechanism not directly demonstrated","pmids":["35149088"],"is_preprint":false},{"year":2024,"finding":"BRCC36 inhibits the Wnt/β-catenin pathway by specifically decreasing K63-linked ubiquitination of β-catenin, attenuating osteogenic differentiation of VSMCs and vascular calcification. This was confirmed by TOPFlash luciferase reporter assay and rescue experiments.","method":"Co-immunoprecipitation; K63-specific ubiquitination assays; TOPFlash luciferase reporter; VSMC-specific overexpression/knockdown; CKD mouse model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — K63-ubiquitination assay on specific substrate (β-catenin) with reporter validation, extends earlier finding, single lab","pmids":["39227917"],"is_preprint":false},{"year":2024,"finding":"BRCC36 in the BRISC complex protects cereblon (CRBN) from lysosomal degradation by specifically cleaving K63-linked polyubiquitin chains on CRBN. SHIN1, which binds SHMT2 (a BRISC subunit), upregulates CRBN by activating BRCC36 in this context.","method":"TurboID proximity labeling; quantitative proteomics; Co-immunoprecipitation; K63-specific ubiquitination assays; lysosomal degradation assays; cell viability assays","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identified by proximity labeling + biochemical validation with linkage-specific ubiquitination assay, single lab","pmids":["39136771"],"is_preprint":false},{"year":2023,"finding":"BRCC3 interacts with TAZ (WWTR1) and the cytoplasmic BRCA1 complex controls TAZ ubiquitination and stability. Loss of BRCC3 or BRCA1 leads to increased TAZ levels and transcriptional activity, linking BRCA1 complex inactivation to TAZ oncogene activation.","method":"siRNA screen; Co-immunoprecipitation; ubiquitination assays; TAZ reporter assays; loss-of-function genetic approaches","journal":"Cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — screen identification with single Co-IP follow-up, limited mechanistic detail in abstract, single lab","pmids":["37887275"],"is_preprint":false},{"year":2019,"finding":"Cyclin-dependent kinase 5 (Cdk5) increases BRCC3 expression levels in a PD cell model; Cdk5 and BRCC3 physically interact (confirmed by co-immunoprecipitation); inhibition of Cdk5 reduces BRCC3 expression and downstream NLRP3 inflammasome activation.","method":"Co-immunoprecipitation; shRNA lentiviral knockdown; pharmacological Cdk5 inhibition; caspase-1 and IL-1β assays","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP for interaction, regulation of expression level rather than direct PTM, single lab","pmids":["31787240"],"is_preprint":false},{"year":2022,"finding":"Cdk5 phosphorylates BRCC3 in vitro; multiple phosphorylation sites were predicted and confirmed by in vitro kinase assay, western blotting, and mass spectrometry using purified His-BRCC3 fusion protein.","method":"In vitro kinase assay; mass spectrometry; western blotting with phospho-specific detection; recombinant protein purification","journal":"Bulletin of experimental biology and medicine","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution with mass spectrometry confirmation, single lab, no mutagenesis validation of specific sites","pmids":["35503584"],"is_preprint":false},{"year":2022,"finding":"TRIM14 recruits USP14 and BRCC3 to form a regulatory complex (TRIM14-USP14-BRCC3) that inhibits OPTN-mediated autophagic degradation of the histone demethylase KDM4D, thereby epigenetically promoting inflammatory gene expression.","method":"Co-immunoprecipitation; autophagy flux assays; inflammatory gene expression readouts (described in brief communication format)","journal":"Autophagy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — complex identification mentioned in a brief report with limited mechanistic detail in abstract, single lab","pmids":["35311471"],"is_preprint":false},{"year":2024,"finding":"BRCC3 deubiquitinates and stabilizes ZEB1 (an EMT transcription factor) in triple-negative breast cancer cells; BRCC3 physically interacts with ZEB1 and reduces its ubiquitination, increasing ZEB1 protein stability and promoting EMT, proliferation, migration, invasion, and metastasis.","method":"Co-immunoprecipitation; ubiquitination assays; protein stability assays (cycloheximide chase implied); siRNA knockdown; in vivo TNBC mouse model","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate (ZEB1) identified by Co-IP and ubiquitination assay with in vivo validation, single lab","pmids":["38449391"],"is_preprint":false},{"year":2024,"finding":"BRCC3 promotes NF-κB signaling in dental pulp cells by expediting IκBα phosphorylation and degradation and p65 nuclear translocation; conditional knockout of Brcc3 in mouse dental pulp cells reduces IL-6, immune cell recruitment, and pulp necrosis after pulp exposure.","method":"RNA-sequencing; dual luciferase reporter assay; immunofluorescence; western blot; conditional Brcc3 knockout mice; pulpitis histology","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with mechanistic endpoint (IκBα/p65 activation) and multiple validation methods, single lab","pmids":["39880291"],"is_preprint":false},{"year":2024,"finding":"BRCC3 (BRCC36) deubiquitinates MET receptor in colon adenocarcinoma cells, stabilizing MET protein and promoting migration, invasion, and EMT; overexpression of MET reverses the effects of BRCC3 knockdown.","method":"Co-immunoprecipitation; ubiquitination assays; shRNA knockdown; rescue with MET overexpression; migration/invasion assays","journal":"Genes & genomics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — substrate identification by Co-IP with rescue experiment, limited mechanistic detail, single lab","pmids":["38470543"],"is_preprint":false},{"year":2024,"finding":"BRCC36 promotes BRCC3 stability by activating the BRCC36-BRG1-mTOR signaling axis in mammary epithelial cells: BRCC36 binds BRG1, inhibits BRG1 protein level and BRG1 binding to the mTOR promoter, thereby suppressing mTOR gene transcription and protein phosphorylation. Methionine decreases BRCC36 protein via ubiquitin-proteasome degradation, thereby relieving suppression of this axis.","method":"Co-immunoprecipitation; chromatin immunoprecipitation (BRG1 on mTOR promoter); BRCC36 knockdown/overexpression; MG132/cycloheximide/chloroquine treatment; ubiquitination assays","journal":"Journal of agricultural and food chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and Co-IP with multiple inhibitor validations, multiple orthogonal methods, single lab","pmids":["38240727"],"is_preprint":false},{"year":2024,"finding":"Molecular glues ('BLUEs') stabilize a 16-subunit BRISC dimer in an autoinhibited conformation, blocking BRCC36 active sites and interactions with the SHMT2 targeting subunit, resulting in selective inhibition of BRISC (K63-linked DUB activity on IFNAR1) without affecting the BRCA1-A complex or other JAMM/MPN DUBs. BLUEs increased IFNAR1 K63-ubiquitylation and decreased IFNAR1 surface levels, reducing interferon-stimulated gene expression.","method":"Cryo-EM structural determination; in vitro DUB activity assays; mutagenesis of inhibitor-binding interface; IFNAR1 ubiquitylation assays; ISG expression in cells with WT vs. inhibitor-resistant BRISC","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure of inhibited complex with mutagenesis validation and orthogonal cellular assays confirming selectivity and mechanism, single preprint study but rigorous","pmids":[],"is_preprint":true}],"current_model":"BRCC3 (BRCC36) is a K63-linked polyubiquitin chain-specific deubiquitinase (JAMM/MPN+ zinc metalloprotease) that functions exclusively within two distinct multisubunit complexes: the nuclear BRCA1-A complex (with ABRAXAS as scaffold, also containing RAP80, BRE, NBA1, and BRCA1) that recognizes RNF8/Ubc13-generated K63-ubiquitin marks at DNA double-strand breaks to regulate DSB end resection and BRCA1 localization, and the cytoplasmic BRISC complex (with ABRO1/KIAA0157 as scaffold and SHMT2 as a regulatory adaptor that can inhibit DUB activity) that controls inflammatory signaling by deubiquitinating NLRP3 inflammasome components, IFNAR1, tankyrase 1, and other substrates; BRCC3 DUB activity is allosterically activated by heterodimerization with the pseudo-DUB ABRO1 or ABRAXAS and requires higher-order super-dimer assembly for full activity and substrate targeting."},"narrative":{"mechanistic_narrative":"BRCC3 (BRCC36) is a K63-linked polyubiquitin chain-specific deubiquitinase that uses a JAMM/MPN+ zinc metalloprotease mechanism rather than an active-site cysteine, and it cleaves K63 chains exclusively, sparing K6-, K11-, K29-, K48-, and alpha-linked chains [PMID:19214193]. Its activity is partitioned between two scaffold-defined multisubunit complexes that share the common subunits BRE and NBA1/MERIT40: the nuclear BRCA1-A complex, organized by the ABRAXAS scaffold together with RAP80, BRCA1/BARD1, and BRCC45, and the cytoplasmic BRISC complex, organized by the ABRO1/KIAA0157 scaffold [PMID:18077395, PMID:20656690, PMID:21282113]. BRCC3 is catalytically inert as a homodimer and is allosterically switched to an active conformation by heterodimerization with the pseudo-DUB scaffolds, with a higher-order 'super-dimer' assembly required for full activity and for engaging targeting subunits such as SHMT2 and RAP80; the adaptor subunits diversify substrate targeting, with ABRAXAS providing a high-affinity BRCA1 site and SHMT2 acting as an inhibitory adaptor on BRISC [PMID:26344097, PMID:31253574]. In the DNA damage response, the BRCA1-A complex is recruited to double-strand breaks through RAP80 UIM binding to RNF8/Ubc13-generated K63 chains, and BRCC3 hydrolase activity counterbalances RNF8 ligase activity to set steady-state ubiquitin levels, limit DSB end resection, and control BRCA1 focus formation and phosphorylation [PMID:18077395, PMID:19202061, PMID:16707425, PMID:27288411]. Through the cytoplasmic BRISC complex, BRCC3 controls inflammatory and immune signaling by deubiquitinating NLRP3 to license inflammasome activation and by acting on IFNAR1 and STAT1 to sustain type I interferon antiviral responses [PMID:23246432, PMID:33857816, PMID:32673428, PMID:31576005]. BRCC3 additionally deubiquitinates and stabilizes a broad set of cell-cycle and signaling substrates including tankyrase 1, ALK2, HMGCR, beta-catenin, and ZEB1, linking it to telomere cohesion, BMP/TGF-beta signaling, vascular calcification, and tumor cell behavior [PMID:27993934, PMID:38557054, PMID:38178583, PMID:39227917, PMID:38449391].","teleology":[{"year":2006,"claim":"Established that BRCC36 is required for the BRCA1 DNA-damage response, the first cellular function assigned to the protein.","evidence":"siRNA knockdown in breast cancer lines with BRCA1/gamma-H2AX foci, phosphorylation, and apoptosis readouts","pmids":["16707425"],"confidence":"Medium","gaps":["Did not define BRCC36 enzymatic activity or substrate","Mechanism of BRCA1 regulation not resolved at molecular level"]},{"year":2007,"claim":"Defined BRCC36 as a subunit of the BRCA1-A complex and mapped how the complex is recruited to DSBs, placing BRCC36 downstream of RNF8/Ubc13 K63 ubiquitin marks.","evidence":"Co-IP, coiled-coil domain mapping, and RNAi of RNF8/Ubc13 with foci assays","pmids":["18077395"],"confidence":"High","gaps":["Catalytic role of BRCC36 within the complex not demonstrated","Did not establish linkage specificity of any DUB activity"]},{"year":2009,"claim":"Identified BRCC36 as the catalytic K63-specific JAMM/MPN+ DUB of the BRISC complex and showed it opposes RNF8-driven ubiquitination at DSBs, unifying its enzymatic identity with its DDR role.","evidence":"Multistep biochemical fractionation with linkage-specific DUB assays; catalytic-mutant epistasis with RNF8 depletion and IR sensitivity","pmids":["19214193","19202061"],"confidence":"High","gaps":["Structural basis of activation not known","Full substrate repertoire at chromatin undefined"]},{"year":2010,"claim":"Showed BRCC36 partitions into two scaffold-defined complexes (nuclear ABRAXAS, cytoplasmic KIAA0157/ABRO1) in dynamic balance, explaining how one DUB serves distinct compartments.","evidence":"Co-IP, subcellular fractionation, siRNA, and in vitro DUB assay on K63-diUb-H2A substrate","pmids":["20656690"],"confidence":"High","gaps":["Mechanism of complex switching not defined","How scaffolds regulate activity unresolved"]},{"year":2011,"claim":"Established BRE and NBA1/MERIT40 as shared subunits whose interaction maintains integrity of both complexes and is required for IR resistance and BRCA1 recruitment.","evidence":"Reciprocal Co-IP, domain mapping, clonogenic survival, and immunofluorescence","pmids":["21282113"],"confidence":"High","gaps":["Did not address cytoplasmic BRISC function","Contribution of these subunits to catalysis unknown"]},{"year":2011,"claim":"Demonstrated an in vivo developmental requirement by showing BRCC3 loss causes angiogenesis defects rescuable by endothelial expression.","evidence":"Zebrafish morpholino knockdown with tissue-specific rescue and vascular imaging","pmids":["21596366"],"confidence":"Medium","gaps":["Molecular substrate driving angiogenesis phenotype not identified","Relationship to DUB activity not tested"]},{"year":2012,"claim":"Identified NLRP3 as a BRISC substrate and BRCC3 as a positive regulator of inflammasome activation, opening its inflammatory signaling role.","evidence":"Pharmacological DUB inhibition, siRNA, ubiquitination and caspase-1/IL-1beta assays","pmids":["23246432"],"confidence":"High","gaps":["Specific ubiquitin chains on NLRP3 not fully mapped","Cellular triggers coupling BRISC to NLRP3 not defined here"]},{"year":2015,"claim":"Resolved the structural basis of activation, showing BRCC36 is inactive as a homodimer, activated by heterodimerization with the pseudo-DUB KIAA0157, and requires a super-dimer for full activity and targeting-subunit binding.","evidence":"X-ray crystallography, DUB assays, interface mutagenesis, SEC/AUC, and pulldowns","pmids":["26344097"],"confidence":"High","gaps":["Did not capture substrate-bound state","Regulation of homodimer-to-heterodimer transition in cells unclear"]},{"year":2016,"claim":"Refined the DDR role by showing BRCC36 catalytic activity limits DSB end resection and BRCA1-A accumulation independently of complex integrity, and identified tankyrase 1 as a cell-cycle-regulated BRISC substrate at telomeres.","evidence":"RNAi/CRISPR catalytic inactivation with resection assays; Co-IP, cell-cycle-staged ubiquitination, and telomere FISH","pmids":["27288411","27993934"],"confidence":"High","gaps":["How catalytic activity selectively limits resection mechanistically unclear","Crosstalk between RNF8 and BRISC at telomeres not fully resolved"]},{"year":2019,"claim":"Provided high-resolution structures of both complexes, revealing ABRAXAS sequesters BRCA1 away from DSBs and SHMT2 acts as an inhibitory adaptor on BRISC, explaining adaptor-driven functional diversification.","evidence":"Cryo-EM and X-ray crystallography with in vitro DUB and binding assays and mutagenesis","pmids":["31253574"],"confidence":"High","gaps":["In vivo control of SHMT2 inhibition not defined","Substrate engagement geometry not captured"]},{"year":2019,"claim":"Linked BRCC3 DUB function to leukemia by showing t(8;21) AML mutations abrogate its activity on IFNAR1 and inflammasome function, with loss promoting self-renewal.","evidence":"CRISPR inactivation, IFNAR1 DUB activity assays, colony-forming and cytokine readouts","pmids":["31576005"],"confidence":"Medium","gaps":["Causal role in leukemogenesis vs. correlation not fully established","Substrate hierarchy in AML cells unresolved"]},{"year":2020,"claim":"Showed BRCC36 is stabilized by ABRO1 competing with the E3 ligase WWP2, and maintains STAT1 noncatalytically via USP13, expanding regulation of and by BRCC36 in antiviral immunity.","evidence":"Competition Co-IP, ubiquitination and degradation assays; STAT1 stability and viral challenge in BRCC36-deficient mice","pmids":["33107021","32673428"],"confidence":"Medium","gaps":["Noncatalytic scaffolding role mechanistically distinct from DUB activity, not structurally defined","In vivo relevance of WWP2 axis incomplete"]},{"year":2021,"claim":"Expanded the substrate and disease landscape by linking BRCC36 to FLT3-ITD K63-ubiquitination in AML and to ICP0-driven degradation of BRCC36 during HSV-1 infection.","evidence":"Proximity labeling, K63-ubiquitination and site mutagenesis, STAT5 readouts; viral infection Co-IP with IFNAR1 readout","pmids":["38288901","33857816"],"confidence":"Medium","gaps":["Whether BRCC36 cleaves vs. reads FLT3-ITD ubiquitin not fully resolved","Generality of viral targeting of BRCC36 unknown"]},{"year":2023,"claim":"Connected BRCC3-NLRP3 deubiquitination to a defined upstream pathway (TET2 loss -> JNK1) in clonal-hematopoiesis-accelerated atherosclerosis, with pharmacological and genetic inhibition reversing disease.","evidence":"Isogenic TET2-deficient macrophages, NLRP3 ubiquitylation assays, Tet2 CH mouse model, ABRO1 hematopoietic KO, holomycin inhibition","pmids":["37781816"],"confidence":"High","gaps":["Direct molecular link from JNK1 to BRCC3 activity not fully defined","Human therapeutic translation untested"]},{"year":2024,"claim":"Broadened the catalytic substrate repertoire and disease links by identifying ALK2, HMGCR, beta-catenin, ZEB1, CRBN, and MET as BRCC3 substrates across vascular, metabolic, and cancer contexts.","evidence":"Co-IP, K63-specific ubiquitination and site mutagenesis assays, catalytic-mutant controls, reporter assays, and mouse models","pmids":["38557054","38178583","39227917","38449391","39136771","38470543"],"confidence":"Medium","gaps":["Many substrates rest on single-lab Co-IP without structural validation","Whether targeting occurs via BRISC, BRCA1-A, or other assemblies not always defined"]},{"year":2024,"claim":"Demonstrated selective pharmacological control of BRISC, providing proof-of-concept that BRCC36 can be inhibited within one complex without affecting the other.","evidence":"Cryo-EM of molecular-glue-stabilized autoinhibited BRISC dimer, DUB and IFNAR1 ubiquitylation assays, inhibitor-resistant mutant validation (preprint)","pmids":[],"confidence":"High","gaps":["Peer review pending","Selectivity and efficacy in vivo not yet established"]},{"year":null,"claim":"How BRCC3 substrate selection is governed across its many reported targets — which assembly, adaptor, and targeting subunit route each substrate to the catalytic core in vivo — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying substrate-recruitment model linking the diverse reported substrates","Most newer substrates rest on single-lab Co-IP without reciprocal or structural validation","Catalytic vs. noncatalytic scaffolding contributions not systematically separated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,3,5,10,20,21,23,24,29]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,9]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,9,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,5,10]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[1,2,3]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[1,2,6,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,16,17,18,19]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,3,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[21,22,23,30]}],"complexes":["BRCA1-A complex","BRISC complex"],"partners":["ABRAXAS","ABRO1","RAP80","BRE","MERIT40","SHMT2","BRCA1","USP13"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P46736","full_name":"Lys-63-specific deubiquitinase BRCC36","aliases":["BRCA1-A complex subunit BRCC36","BRCA1/BRCA2-containing complex subunit 3","BRCA1/BRCA2-containing complex subunit 36","BRISC complex subunit BRCC36"],"length_aa":316,"mass_kda":36.1,"function":"Metalloprotease that specifically cleaves 'Lys-63'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Does not have activity toward 'Lys-48'-linked polyubiquitin chains (PubMed:19214193, PubMed:20656690, PubMed:24075985, PubMed:26344097). Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs) (PubMed:14636569, PubMed:16707425, PubMed:17525341, PubMed:19202061, PubMed:19261746, PubMed:19261748, PubMed:19261749). In the BRCA1-A complex, it specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX, antagonizing the RNF8-dependent ubiquitination at double-strand breaks (DSBs) (PubMed:20656690). Catalytic subunit of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:20656690, PubMed:24075985, PubMed:26195665, PubMed:26344097). Mediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Acts as a regulator of the NLRP3 inflammasome by mediating deubiquitination of NLRP3, leading to NLRP3 inflammasome assembly (By similarity). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). Deubiquitinates HDAC1 and PWWP2B leading to their stabilization (By similarity)","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, cytoskeleton, spindle pole","url":"https://www.uniprot.org/uniprotkb/P46736/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BRCC3","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BRCC3","total_profiled":1310},"omim":[{"mim_id":"612766","title":"BRISC AND BRCA1 A COMPLEX, MEMBER 1; BABAM1","url":"https://www.omim.org/entry/612766"},{"mim_id":"612688","title":"RING FINGER PROTEIN 168; RNF168","url":"https://www.omim.org/entry/612688"},{"mim_id":"610497","title":"BRISC AND BRCA1 A COMPLEX, MEMBER 2; BABAM2","url":"https://www.omim.org/entry/610497"},{"mim_id":"608413","title":"UBIQUITIN-PROTEIN LIGASE E3 COMPONENT N-RECOGNIN 5; UBR5","url":"https://www.omim.org/entry/608413"},{"mim_id":"602027","title":"TELOMERIC REPEAT-BINDING FACTOR 2; TERF2","url":"https://www.omim.org/entry/602027"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRCC3"},"hgnc":{"alias_symbol":["C6.1A","BRCC36"],"prev_symbol":["CXorf53"]},"alphafold":{"accession":"P46736","domains":[{"cath_id":"3.40.140.10","chopping":"8-47_69-179_207-222","consensus_level":"medium","plddt":92.7077,"start":8,"end":222},{"cath_id":"1.10.287","chopping":"227-316","consensus_level":"medium","plddt":96.0144,"start":227,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P46736","model_url":"https://alphafold.ebi.ac.uk/files/AF-P46736-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P46736-F1-predicted_aligned_error_v6.png","plddt_mean":84.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRCC3","jax_strain_url":"https://www.jax.org/strain/search?query=BRCC3"},"sequence":{"accession":"P46736","fasta_url":"https://rest.uniprot.org/uniprotkb/P46736.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P46736/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P46736"}},"corpus_meta":[{"pmid":"23246432","id":"PMC_23246432","title":"Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23246432","citation_count":588,"is_preprint":false},{"pmid":"18077395","id":"PMC_18077395","title":"Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18077395","citation_count":357,"is_preprint":false},{"pmid":"19214193","id":"PMC_19214193","title":"K63-specific deubiquitination by two JAMM/MPN+ complexes: BRISC-associated Brcc36 and proteasomal Poh1.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19214193","citation_count":194,"is_preprint":false},{"pmid":"19202061","id":"PMC_19202061","title":"The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19202061","citation_count":184,"is_preprint":false},{"pmid":"20656690","id":"PMC_20656690","title":"The Lys63-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20656690","citation_count":103,"is_preprint":false},{"pmid":"28238526","id":"PMC_28238526","title":"Mitochondrial DNA oxidation induces imbalanced activity of NLRP3/NLRP6 inflammasomes by activation of caspase-8 and BRCC36 in dry eye.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28238526","citation_count":97,"is_preprint":false},{"pmid":"21596366","id":"PMC_21596366","title":"Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21596366","citation_count":96,"is_preprint":false},{"pmid":"31866999","id":"PMC_31866999","title":"Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31866999","citation_count":95,"is_preprint":false},{"pmid":"37781816","id":"PMC_37781816","title":"BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/37781816","citation_count":70,"is_preprint":false},{"pmid":"30347231","id":"PMC_30347231","title":"LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis.","date":"2018","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/30347231","citation_count":68,"is_preprint":false},{"pmid":"16707425","id":"PMC_16707425","title":"BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16707425","citation_count":67,"is_preprint":false},{"pmid":"31253574","id":"PMC_31253574","title":"Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31253574","citation_count":65,"is_preprint":false},{"pmid":"21282113","id":"PMC_21282113","title":"NBA1/MERIT40 and BRE interaction is required for the integrity of two distinct deubiquitinating enzyme BRCC36-containing complexes.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21282113","citation_count":62,"is_preprint":false},{"pmid":"26344097","id":"PMC_26344097","title":"Higher-Order Assembly of BRCC36-KIAA0157 Is Required for DUB Activity and Biological Function.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26344097","citation_count":53,"is_preprint":false},{"pmid":"17143545","id":"PMC_17143545","title":"Expression of BRCC3, a novel cell cycle regulated molecule, is associated with increased phospho-ERK and cell proliferation.","date":"2007","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17143545","citation_count":44,"is_preprint":false},{"pmid":"29791506","id":"PMC_29791506","title":"SHMT2 and the BRCC36/BRISC deubiquitinase regulate HIV-1 Tat K63-ubiquitylation and destruction by autophagy.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29791506","citation_count":43,"is_preprint":false},{"pmid":"27288411","id":"PMC_27288411","title":"The Lys63-deubiquitylating Enzyme BRCC36 Limits DNA Break Processing and Repair.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27288411","citation_count":40,"is_preprint":false},{"pmid":"38178583","id":"PMC_38178583","title":"BRCC36 Deubiquitinates HMGCR to Regulate the Interplay Between Ferroptosis and Pyroptosis.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38178583","citation_count":39,"is_preprint":false},{"pmid":"33295056","id":"PMC_33295056","title":"Long noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K/Akt/mTOR pathway.","date":"2021","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33295056","citation_count":39,"is_preprint":false},{"pmid":"37681916","id":"PMC_37681916","title":"miR-369-3p Modulates Intestinal Inflammatory Response via BRCC3/NLRP3 Inflammasome Axis.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37681916","citation_count":34,"is_preprint":false},{"pmid":"27993934","id":"PMC_27993934","title":"Cell cycle-regulated ubiquitination of tankyrase 1 by RNF8 and ABRO1/BRCC36 controls the timing of sister telomere resolution.","date":"2016","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/27993934","citation_count":33,"is_preprint":false},{"pmid":"31485755","id":"PMC_31485755","title":"Regulation of oxidized LDL-induced inflammatory process through NLRP3 inflammasome activation by the deubiquitinating enzyme BRCC36.","date":"2019","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/31485755","citation_count":33,"is_preprint":false},{"pmid":"31787240","id":"PMC_31787240","title":"The BRCC3 regulated by Cdk5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson's disease models.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31787240","citation_count":30,"is_preprint":false},{"pmid":"38557054","id":"PMC_38557054","title":"BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/38557054","citation_count":28,"is_preprint":false},{"pmid":"26001790","id":"PMC_26001790","title":"BRCC3 mutations in myeloid neoplasms.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/26001790","citation_count":25,"is_preprint":false},{"pmid":"38544474","id":"PMC_38544474","title":"BRCC3 mediates inflammation and pyroptosis in cerebral ischemia/reperfusion injury by activating the NLRP6 inflammasome.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38544474","citation_count":23,"is_preprint":false},{"pmid":"27175567","id":"PMC_27175567","title":"B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27175567","citation_count":23,"is_preprint":false},{"pmid":"31576005","id":"PMC_31576005","title":"Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).","date":"2019","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/31576005","citation_count":22,"is_preprint":false},{"pmid":"36600050","id":"PMC_36600050","title":"Inhibition of CD82 improves colitis by increasing NLRP3 deubiquitination by BRCC3.","date":"2023","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36600050","citation_count":20,"is_preprint":false},{"pmid":"34604222","id":"PMC_34604222","title":"BRCC3 Promotes Tumorigenesis of Bladder Cancer by Activating the NF-κB Signaling Pathway Through Targeting TRAF2.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34604222","citation_count":20,"is_preprint":false},{"pmid":"33107021","id":"PMC_33107021","title":"ABRO1 stabilizes the deubiquitinase BRCC3 through inhibiting its degradation mediated by the E3 ubiquitin ligase WWP2.","date":"2020","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/33107021","citation_count":18,"is_preprint":false},{"pmid":"33979701","id":"PMC_33979701","title":"BRCC3 promotes activation of the NLRP6 inflammasome following cerebral ischemia/reperfusion (I/R) injury in rats.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/33979701","citation_count":16,"is_preprint":false},{"pmid":"30272359","id":"PMC_30272359","title":"Knockdown of BRCC3 exerts an anti‑tumor effect on cervical cancer in vitro.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30272359","citation_count":15,"is_preprint":false},{"pmid":"34850961","id":"PMC_34850961","title":"Inhibition of lncRNA NEAT1 protects endothelial cells against hypoxia/reoxygenation‑induced NLRP3 inflammasome activation by targeting the miR‑204/BRCC3 axis.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/34850961","citation_count":14,"is_preprint":false},{"pmid":"38288901","id":"PMC_38288901","title":"BRCC36 associates with FLT3-ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/38288901","citation_count":12,"is_preprint":false},{"pmid":"33857816","id":"PMC_33857816","title":"HSV-1-encoded ICP0 degrades the host deubiquitinase BRCC36 to antagonize interferon antiviral response.","date":"2021","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33857816","citation_count":12,"is_preprint":false},{"pmid":"35149088","id":"PMC_35149088","title":"BRCC36 prevents vascular calcification in chronic kidney disease through the β-catenin signalling pathway.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35149088","citation_count":10,"is_preprint":false},{"pmid":"37361896","id":"PMC_37361896","title":"Vitamin D3 attenuates SARS-CoV-2 nucleocapsid protein-caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway in vitro and in vivo.","date":"2023","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/37361896","citation_count":10,"is_preprint":false},{"pmid":"38449391","id":"PMC_38449391","title":"The deubiquitinase BRCC3 increases the stability of ZEB1 and promotes the proliferation and metastasis of triple-negative breast cancer cells.","date":"2024","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38449391","citation_count":8,"is_preprint":false},{"pmid":"39642564","id":"PMC_39642564","title":"Deletion of BRCC3 ameliorates airway inflammation in asthma by inhibiting the activation of NLRP3 inflammasome.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39642564","citation_count":8,"is_preprint":false},{"pmid":"39136771","id":"PMC_39136771","title":"Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39136771","citation_count":7,"is_preprint":false},{"pmid":"32673428","id":"PMC_32673428","title":"BRCC36 functions noncatalytically to promote antiviral response by maintaining STAT1 protein stability.","date":"2020","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32673428","citation_count":7,"is_preprint":false},{"pmid":"39227917","id":"PMC_39227917","title":"BRCC36 regulates β-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39227917","citation_count":6,"is_preprint":false},{"pmid":"37564930","id":"PMC_37564930","title":"UCA1 executes an oncogenic role in pancreatic cancer by regulating miR-582-5p/BRCC3.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37564930","citation_count":6,"is_preprint":false},{"pmid":"35311471","id":"PMC_35311471","title":"The TRIM14-USP14-BRCC3 complex epigenetically regulates inflammation through inhibiting OPTN-mediated autophagic degradation of KDM4D.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35311471","citation_count":5,"is_preprint":false},{"pmid":"34888627","id":"PMC_34888627","title":"BRCC36 promotes intestinal mucosal barrier injury caused by BMP2 after ischemia reperfusion via inhibiting PPARγ signaling.","date":"2022","source":"Bioscience, biotechnology, and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34888627","citation_count":5,"is_preprint":false},{"pmid":"37887275","id":"PMC_37887275","title":"Identification of BRCC3 and BRCA1 as Regulators of TAZ Stability and Activity.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37887275","citation_count":3,"is_preprint":false},{"pmid":"38240727","id":"PMC_38240727","title":"Methionine Promotes Milk Synthesis through the BRCC36-BRG1-mTOR Signaling Axis in Mammary Epithelial Cells.","date":"2024","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38240727","citation_count":3,"is_preprint":false},{"pmid":"39880291","id":"PMC_39880291","title":"BRCC3 aggravates pulpitis by activating the NF-κB signaling pathway in dental pulp cells.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39880291","citation_count":2,"is_preprint":false},{"pmid":"39552268","id":"PMC_39552268","title":"BRCC3 -Associated Syndromic Moyamoya Angiopathy Diagnosed Through Clinical RNA Sequencing.","date":"2024","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39552268","citation_count":2,"is_preprint":false},{"pmid":"38470543","id":"PMC_38470543","title":"Deubiquitinase BRCC3 promotes the migration, invasion and EMT progression of colon adenocarcinoma by stabilizing MET expression.","date":"2024","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38470543","citation_count":1,"is_preprint":false},{"pmid":"41463377","id":"PMC_41463377","title":"Complexes Formed by the K63-Specific Deubiquitinating Enzyme BRCC36: New Promising Therapeutic Targets in Human Disease.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41463377","citation_count":1,"is_preprint":false},{"pmid":"39596176","id":"PMC_39596176","title":"Loss of Brcc3 in Zebrafish Embryos Increases Their Susceptibility to DNA Damage Stress.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39596176","citation_count":0,"is_preprint":false},{"pmid":"35503584","id":"PMC_35503584","title":"Identification and Verification of the Ability of Cdk5 to Phosphorylate Deubiquitinating Enzyme BRCC3 In Vitro.","date":"2022","source":"Bulletin of experimental biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35503584","citation_count":0,"is_preprint":false},{"pmid":"41891972","id":"PMC_41891972","title":"Mechanism of BRCC36 affecting cardiac rupture after acute infarction through the Wnt‑JNK signaling pathway.","date":"2026","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/41891972","citation_count":0,"is_preprint":false},{"pmid":"41638058","id":"PMC_41638058","title":"Paeonol alleviates pulmonary arterial hypertension by activation of BRCC3.","date":"2026","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41638058","citation_count":0,"is_preprint":false},{"pmid":"42090613","id":"PMC_42090613","title":"Post-transcriptional knockdown of BRCC3 via siRNA-loaded niosomes modulates autophagy and endoplasmic reticulum stress in rotenone-induced Parkinson's Disease model.","date":"2026","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/42090613","citation_count":0,"is_preprint":false},{"pmid":"42214739","id":"PMC_42214739","title":"Thiolutin ameliorates postoperative cognitive dysfunction induced by intestinal ischemia-reperfusion in aged mice: a potential role for modulation of the BRCC3/NLRP3 axis.","date":"2026","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/42214739","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.03.652026","title":"<i>In silico</i>  analysis and Predictive linkage of Deubiquitinating Enzymes underlying Early Development","date":"2025-05-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.03.652026","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.27.24314321","title":"Risk of Clonal Hematopoiesis of Indeterminate Potential after Cancer Radiation Therapy","date":"2024-09-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.27.24314321","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.07.611787","title":"Molecular glues that inhibit deubiquitylase activity and inflammatory signalling","date":"2024-09-07","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.07.611787","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":33279,"output_tokens":9063,"usd":0.117891,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19020,"output_tokens":5356,"usd":0.1145,"stage2_stop_reason":"end_turn"},"total_usd":0.232391,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"BRCC36 (BRCC3) is the catalytic subunit of the BRISC complex and exhibits K63-linked polyubiquitin chain-specific deubiquitinating (DUB) activity; it lacks an active-site cysteine and instead uses a JAMM/MPN+ zinc metalloprotease mechanism. The K63-specific DUB activity is intrinsic to the BRISC complex and does not cleave K6, K11, K29, K48, or alpha-linked chains.\",\n      \"method\": \"Biochemical fractionation through seven chromatographic steps; fluorometric DUB assays with linkage-specific ubiquitin substrates; NEM/ubiquitin-aldehyde insensitivity tests\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with defined substrates, multiple orthogonal biochemical methods, linkage specificity rigorously demonstrated\",\n      \"pmids\": [\"19214193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BRCC36 (BRCC3) is a component of the BRCA1-A complex (also containing BRCA1/BARD1, ABRAXAS/CCDC98, RAP80, BRCC45/BRE, MERIT40). BRCC36 associates with ABRAXAS via coiled-coil domains on each protein, and RAP80 contains an Abraxas-interacting region (AIR) required for association of RAP80 with ABRAXAS, BRCA1, and BRCC36. The entire complex is recruited to DNA double-strand break (DSB) foci through RAP80 UIM-domain binding to RNF8/Ubc13-generated K63-linked polyubiquitin chains.\",\n      \"method\": \"Co-immunoprecipitation; domain mapping; RNAi knockdown of RNF8/Ubc13 with immunofluorescence foci assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and domain mapping, replicated in multiple independent labs\",\n      \"pmids\": [\"18077395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The RAP80-BRCC36 complex opposes RNF8-Ubc13-dependent ubiquitination at DSBs. BRCC36 knockdown or expression of a DUB-inactive BRCC36 mutant rescued 53BP1 recruitment and γ-H2AX ubiquitination following RNF8 depletion, demonstrating that BRCC36 hydrolase activity counterbalances RNF8 ubiquitin ligase activity to set steady-state ubiquitin levels at DSBs.\",\n      \"method\": \"siRNA knockdown; DUB-inactive mutant expression; immunofluorescence; ionizing radiation sensitivity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with catalytic mutant, replicated with multiple approaches, independent lab from PMID:18077395\",\n      \"pmids\": [\"19202061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BRCC36 exists in two distinct subcellular complexes determined by two scaffold proteins: nuclear ABRAXAS/CCDC98 (within the BRCA1-A complex) and cytoplasmic KIAA0157 (ABRO1, within BRISC). ABRAXAS and KIAA0157 each regulate BRCC36 DUB activity. Reduction of KIAA0157 increases the BRCA1-A complex in the nucleus, indicating the two complexes are in dynamic balance. BRCC36 reduces K63-linked ubiquitin chains at chromatin and deubiquitinates diubiquitinated histone H2A.\",\n      \"method\": \"Co-immunoprecipitation; subcellular fractionation; siRNA knockdown; in vitro DUB assays with K63-linked diubiquitin-H2A substrate\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro DUB assay on defined substrate plus Co-IP, fractionation, and RNAi with functional consequence, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20656690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Both the nuclear BRCA1-A (ABRAXAS-containing) and cytoplasmic BRISC (ABRO1-containing) complexes share the common subunits BRE and NBA1/MERIT40. NBA1 and BRE interact through a C-terminal conserved motif of NBA1 and the C-terminal UEV domain of BRE; this interaction is essential for maintaining the integrity of both complexes and for cellular resistance to ionizing radiation and BRCA1 recruitment to DSBs.\",\n      \"method\": \"Co-immunoprecipitation; domain deletion/mutation mapping; siRNA knockdown; clonogenic survival assays; immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with domain mapping, functional validation by clonogenic assay, multiple orthogonal methods single lab\",\n      \"pmids\": [\"21282113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BRCC3 (BRCC36) deubiquitinates NLRP3 and acts as a critical positive regulator of NLRP3 inflammasome activation. NLRP3 is a substrate of the cytosolic BRISC complex containing BRCC3. Pharmacological and siRNA-mediated inhibition of BRCC3 DUB activity suppresses NLRP3 inflammasome activation.\",\n      \"method\": \"Pharmacological DUB inhibition; siRNA knockdown; ubiquitination assays; caspase-1 and IL-1β activity assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (pharmacological + genetic), substrate identification, widely replicated by independent labs\",\n      \"pmids\": [\"23246432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BRCC36 (BRCC3) regulates BRCA1 activation in response to DNA damage: knockdown of BRCC36 disrupts ionizing radiation-induced BRCA1 phosphorylation and prevents formation of BRCA1 nuclear foci at DSBs, sensitizing breast cancer cells to IR-induced apoptosis. BRCC36 regulates ubiquitin E3 ligase activity of the BRCC complex.\",\n      \"method\": \"siRNA knockdown in MCF-7, ZR-75-1, T47D cells; immunoblot; immunofluorescence of BRCA1 and γ-H2AX foci; apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined cellular phenotype (foci, phosphorylation, apoptosis), single lab, multiple cell lines\",\n      \"pmids\": [\"16707425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss of BRCC3 function in zebrafish (brcc3 morphants) causes angiogenesis defects that are rescued by endothelium-specific expression of brcc3, establishing BRCC3 as an essential regulator of angiogenesis in vivo.\",\n      \"method\": \"Morpholino knockdown in zebrafish; rescue by endothelium-specific BRCC3 expression; vascular imaging\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiment in zebrafish ortholog with tissue-specific complementation, single lab\",\n      \"pmids\": [\"21596366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Structural characterization of the BRCC36-KIAA0157 (ABRO1) heterodimer reveals BRCC36 is activated by contacts with the pseudo-DUB KIAA0157 (MPN− domain). An inactive BRCC36 homodimer exists; heterodimerization with KIAA0157 switches BRCC36 to an active conformation. Furthermore, a higher-order dimer-of-heterodimers ('super-dimer') assembly is required for full DUB activity and for interactions with targeting proteins SHMT2 and RAP80.\",\n      \"method\": \"X-ray crystallography; in vitro DUB activity assays; mutagenesis of interface residues; size-exclusion chromatography/analytical ultracentrifugation; pulldown assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus in vitro reconstitution, mutagenesis, and functional validation in single rigorous study\",\n      \"pmids\": [\"26344097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRCC36 DUB activity within the BRCA1-A complex limits DSB end resection and DNA repair. Inactivation of BRCC36 DUB (via RNAi or CRISPR editing) attenuated BRCA1-A complex accumulation at DSBs and led to unrestrained DSB end resection and hyperactive DNA repair, while the structural integrity of the complex was maintained.\",\n      \"method\": \"RNAi; CRISPR/Cas9 genome editing; catalytic mutant expression; end resection assays; BRCA1-A foci quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — catalytic mutant plus CRISPR KO with mechanistic endpoint (resection), two orthogonal genetic approaches\",\n      \"pmids\": [\"27288411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The BRISC complex (ABRO1/BRCC36) removes K63-linked ubiquitin chains from tankyrase 1 in G1 phase, while RNF8 adds K63-linked ubiquitin chains in late S/G2. This ubiquitination/deubiquitination cycle controls tankyrase 1 stabilization, telomere association, and resolution of sister telomere cohesion in a cell cycle-regulated manner.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; cell cycle synchronization; telomere FISH; siRNA knockdown of ABRO1/BRCC36\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identification with cell-cycle-staged ubiquitination assays, genetic epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"27993934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal/cryo-EM structures of the BRCA1-A and BRISC complexes reveal: (1) In BRCA1-A, ABRAXAS integrates RAP80 and provides a high-affinity BRCA1-binding site that sequesters BRCA1 away from DSBs. (2) In BRISC, ABRO1 binds the metabolic enzyme SHMT2α, which in this context prevents BRCC36 from binding and cleaving ubiquitin chains (inhibitory regulation). Different adaptor subunits thus confer diversified targeting and regulatory functions on the same BRCC36 catalytic subunit.\",\n      \"method\": \"Cryo-EM and X-ray crystallography; in vitro DUB activity assays; binding assays; mutagenesis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution structures of both complexes combined with in vitro functional validation and mutagenesis in single rigorous study\",\n      \"pmids\": [\"31253574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SHMT2 acts as a regulatory adaptor in the BRISC complex: SHMT2 and BRCC36 (via BRISC) regulate HIV-1 Tat K63-ubiquitylation. Knockdown of SHMT1/2 or BRCC36 strongly increased K63-Ub-dependent autophagic destruction of Tat; point mutation of multiple lysines in Tat or knockdown of BRCC36/SHMT1,2 prevented JIB-04-induced Tat destruction.\",\n      \"method\": \"Proximity proteomics (DiffPOP); mass spectrometry; siRNA knockdown; Tat ubiquitination assays; autophagy flux assays; site-directed mutagenesis of Tat lysines\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (proteomics, mutagenesis, genetic KD) in single lab\",\n      \"pmids\": [\"29791506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Vitamin D receptor (VDR) physically binds NLRP3 and blocks the association of NLRP3 with BRCC3, thereby preventing BRCC3-mediated deubiquitination and subsequent NLRP3 activation. VDR thus acts as a negative regulator of NLRP3 by competing with BRCC3 for NLRP3 binding.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; VDR knockout mice; IL-1β/caspase-1 activation assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP demonstrating competitive binding, in vivo KO validation, single lab with multiple methods\",\n      \"pmids\": [\"31866999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ABRO1 stabilizes BRCC3 protein by competing with the HECT-type E3 ubiquitin ligase WWP2 for binding to BRCC3, thereby preventing WWP2-mediated K48-linked ubiquitination and proteasomal degradation of BRCC3. WWP2 overexpression in macrophages inhibits NLRP3 inflammasome activation by reducing BRCC3 levels.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; cycloheximide chase; siRNA/lentiviral overexpression; caspase-1 and IL-1β assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (competition Co-IP, degradation assays, functional readout) in single lab\",\n      \"pmids\": [\"33107021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRCC36 (BRCC3) specifically associates with FLT3-ITD (but not wild-type FLT3 or FLT3-TKD) through K63-linked polyubiquitination at K609 of the ITD mutant. BRCC36 knockdown decreases STAT5 phosphorylation and cell proliferation in FLT3-ITD AML cells.\",\n      \"method\": \"Proximity labeling (TurboID); K63-ubiquitination assays; site-directed mutagenesis (K609R); siRNA knockdown; phospho-STAT5 immunoblot; cell proliferation assays\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity labeling plus mutagenesis of ubiquitination site and functional validation, single lab\",\n      \"pmids\": [\"38288901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HSV-1-encoded ICP0 induces K48-linked polyubiquitination and proteasomal degradation of BRCC36, leading to downmodulation of IFN-I receptor IFNAR1 and suppression of the host type I interferon antiviral response.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; viral infection time-courses; immunoblot; IFNAR1 surface level measurement\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — viral protein-host DUB interaction identified by Co-IP with mechanistic downstream readout (IFNAR1), single lab\",\n      \"pmids\": [\"33857816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRCC36 maintains STAT1 protein stability noncatalytically by recruiting USP13 to form a complex that antagonizes Smurf1-mediated STAT1 degradation. BRCC36 deficiency causes rapid STAT1 downregulation during viral infection, impairing antiviral immunity in vivo.\",\n      \"method\": \"Co-immunoprecipitation; STAT1 stability assays; viral challenge in BRCC36-deficient mice; USP13/Smurf1 epistasis experiments\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complex identification by Co-IP with in vivo validation and genetic epistasis, single lab\",\n      \"pmids\": [\"32673428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In TET2-deficient macrophages, increased JNK1 signaling (due to hypermethylation and decreased expression of the phosphatase DUSP10) promotes BRCC3-mediated NLRP3 deubiquitylation and inflammasome activation, accelerating atherosclerosis. The BRCC3 inhibitor holomycin or hematopoietic deficiency of ABRO1 (essential BRISC scaffolding protein) reversed accelerated atherosclerosis and NETosis in Tet2 CH mice.\",\n      \"method\": \"Cholesterol-loaded TET2-deficient macrophages (murine and human ESC-derived isogenic); JNK1 phosphorylation assays; NLRP3 ubiquitylation assays; Tet2 CH mouse atherosclerosis model; ABRO1 hematopoietic KO; holomycin pharmacological inhibition\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pathway epistasis (JNK1→BRCC3→NLRP3), pharmacological and genetic inhibition, both murine and human models, independent validation of ABRO1 scaffolding requirement\",\n      \"pmids\": [\"37781816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRCC3 mutations in AML with t(8;21) abrogate its DUB activity on IFNAR1, resulting in impaired interferon response, and also diminish inflammasome activity. BRCC3 inactivation by CRISPR/Cas9 in t(8;21) AML cell lines improved proliferation and, combined with AML1-ETO, induced unlimited self-renewal of mouse hematopoietic progenitors.\",\n      \"method\": \"CRISPR/Cas9 inactivation; DUB activity assays on IFNAR1 substrate; interferon response assays; colony-forming assays; cytokine profiling\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with defined biochemical endpoint (DUB activity on IFNAR1) and multiple functional readouts, single lab\",\n      \"pmids\": [\"31576005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC36 deubiquitinates HMGCR in a DUB-activity-dependent manner, stabilizing HMGCR and suppressing ferroptosis while promoting pyroptosis in hepatocellular carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; DUB-inactive mutant; cell death assays (ferroptosis/pyroptosis markers); in vivo xenograft model with thiolutin (BRCC36 inhibitor)\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identified by Co-IP and ubiquitination assay with catalytic mutant control, single lab\",\n      \"pmids\": [\"38178583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC3 deubiquitinates ALK2 at Lys-472 and Lys-475 (K63-linked), activating receptor-regulated Smad1/5/9 and transcriptional activation of BMP-regulated PPARγ, p53, and Id1. BRCC3 also attenuates TGF-β signaling by downregulating TGF-β expression and inhibiting Smad3 phosphorylation. Smooth muscle cell-specific BRCC3 transgenic mice are protected from experimental pulmonary hypertension, while Brcc3−/− mice show increased susceptibility.\",\n      \"method\": \"Bioinformatic ubiquitination site prediction; site-directed mutagenesis (K472/475R ALK2); Co-immunoprecipitation; ubiquitination assays; SM22α-BRCC3-Tg and Brcc3−/− mouse models; pulmonary hemodynamics\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — site-specific mutagenesis confirming ubiquitination sites, gain-of-function and loss-of-function mouse models, multiple downstream pathway readouts\",\n      \"pmids\": [\"38557054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRCC36 binds β-catenin and inhibits its phosphorylation; BRCC36 overexpression reduces phosphorylated β-catenin levels in the nucleus and calcium deposition in VSMCs, negatively regulating the Wnt/β-catenin pathway to prevent vascular calcification.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence; Alizarin red staining; calcium content assays; overexpression/knockdown in VSMCs and CKD mouse model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP of interaction with functional outcome in two model systems, single lab, β-catenin deubiquitination mechanism not directly demonstrated\",\n      \"pmids\": [\"35149088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC36 inhibits the Wnt/β-catenin pathway by specifically decreasing K63-linked ubiquitination of β-catenin, attenuating osteogenic differentiation of VSMCs and vascular calcification. This was confirmed by TOPFlash luciferase reporter assay and rescue experiments.\",\n      \"method\": \"Co-immunoprecipitation; K63-specific ubiquitination assays; TOPFlash luciferase reporter; VSMC-specific overexpression/knockdown; CKD mouse model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — K63-ubiquitination assay on specific substrate (β-catenin) with reporter validation, extends earlier finding, single lab\",\n      \"pmids\": [\"39227917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC36 in the BRISC complex protects cereblon (CRBN) from lysosomal degradation by specifically cleaving K63-linked polyubiquitin chains on CRBN. SHIN1, which binds SHMT2 (a BRISC subunit), upregulates CRBN by activating BRCC36 in this context.\",\n      \"method\": \"TurboID proximity labeling; quantitative proteomics; Co-immunoprecipitation; K63-specific ubiquitination assays; lysosomal degradation assays; cell viability assays\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identified by proximity labeling + biochemical validation with linkage-specific ubiquitination assay, single lab\",\n      \"pmids\": [\"39136771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRCC3 interacts with TAZ (WWTR1) and the cytoplasmic BRCA1 complex controls TAZ ubiquitination and stability. Loss of BRCC3 or BRCA1 leads to increased TAZ levels and transcriptional activity, linking BRCA1 complex inactivation to TAZ oncogene activation.\",\n      \"method\": \"siRNA screen; Co-immunoprecipitation; ubiquitination assays; TAZ reporter assays; loss-of-function genetic approaches\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — screen identification with single Co-IP follow-up, limited mechanistic detail in abstract, single lab\",\n      \"pmids\": [\"37887275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cyclin-dependent kinase 5 (Cdk5) increases BRCC3 expression levels in a PD cell model; Cdk5 and BRCC3 physically interact (confirmed by co-immunoprecipitation); inhibition of Cdk5 reduces BRCC3 expression and downstream NLRP3 inflammasome activation.\",\n      \"method\": \"Co-immunoprecipitation; shRNA lentiviral knockdown; pharmacological Cdk5 inhibition; caspase-1 and IL-1β assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP for interaction, regulation of expression level rather than direct PTM, single lab\",\n      \"pmids\": [\"31787240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cdk5 phosphorylates BRCC3 in vitro; multiple phosphorylation sites were predicted and confirmed by in vitro kinase assay, western blotting, and mass spectrometry using purified His-BRCC3 fusion protein.\",\n      \"method\": \"In vitro kinase assay; mass spectrometry; western blotting with phospho-specific detection; recombinant protein purification\",\n      \"journal\": \"Bulletin of experimental biology and medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution with mass spectrometry confirmation, single lab, no mutagenesis validation of specific sites\",\n      \"pmids\": [\"35503584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TRIM14 recruits USP14 and BRCC3 to form a regulatory complex (TRIM14-USP14-BRCC3) that inhibits OPTN-mediated autophagic degradation of the histone demethylase KDM4D, thereby epigenetically promoting inflammatory gene expression.\",\n      \"method\": \"Co-immunoprecipitation; autophagy flux assays; inflammatory gene expression readouts (described in brief communication format)\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — complex identification mentioned in a brief report with limited mechanistic detail in abstract, single lab\",\n      \"pmids\": [\"35311471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC3 deubiquitinates and stabilizes ZEB1 (an EMT transcription factor) in triple-negative breast cancer cells; BRCC3 physically interacts with ZEB1 and reduces its ubiquitination, increasing ZEB1 protein stability and promoting EMT, proliferation, migration, invasion, and metastasis.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; protein stability assays (cycloheximide chase implied); siRNA knockdown; in vivo TNBC mouse model\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate (ZEB1) identified by Co-IP and ubiquitination assay with in vivo validation, single lab\",\n      \"pmids\": [\"38449391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC3 promotes NF-κB signaling in dental pulp cells by expediting IκBα phosphorylation and degradation and p65 nuclear translocation; conditional knockout of Brcc3 in mouse dental pulp cells reduces IL-6, immune cell recruitment, and pulp necrosis after pulp exposure.\",\n      \"method\": \"RNA-sequencing; dual luciferase reporter assay; immunofluorescence; western blot; conditional Brcc3 knockout mice; pulpitis histology\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with mechanistic endpoint (IκBα/p65 activation) and multiple validation methods, single lab\",\n      \"pmids\": [\"39880291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC3 (BRCC36) deubiquitinates MET receptor in colon adenocarcinoma cells, stabilizing MET protein and promoting migration, invasion, and EMT; overexpression of MET reverses the effects of BRCC3 knockdown.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays; shRNA knockdown; rescue with MET overexpression; migration/invasion assays\",\n      \"journal\": \"Genes & genomics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — substrate identification by Co-IP with rescue experiment, limited mechanistic detail, single lab\",\n      \"pmids\": [\"38470543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRCC36 promotes BRCC3 stability by activating the BRCC36-BRG1-mTOR signaling axis in mammary epithelial cells: BRCC36 binds BRG1, inhibits BRG1 protein level and BRG1 binding to the mTOR promoter, thereby suppressing mTOR gene transcription and protein phosphorylation. Methionine decreases BRCC36 protein via ubiquitin-proteasome degradation, thereby relieving suppression of this axis.\",\n      \"method\": \"Co-immunoprecipitation; chromatin immunoprecipitation (BRG1 on mTOR promoter); BRCC36 knockdown/overexpression; MG132/cycloheximide/chloroquine treatment; ubiquitination assays\",\n      \"journal\": \"Journal of agricultural and food chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and Co-IP with multiple inhibitor validations, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"38240727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Molecular glues ('BLUEs') stabilize a 16-subunit BRISC dimer in an autoinhibited conformation, blocking BRCC36 active sites and interactions with the SHMT2 targeting subunit, resulting in selective inhibition of BRISC (K63-linked DUB activity on IFNAR1) without affecting the BRCA1-A complex or other JAMM/MPN DUBs. BLUEs increased IFNAR1 K63-ubiquitylation and decreased IFNAR1 surface levels, reducing interferon-stimulated gene expression.\",\n      \"method\": \"Cryo-EM structural determination; in vitro DUB activity assays; mutagenesis of inhibitor-binding interface; IFNAR1 ubiquitylation assays; ISG expression in cells with WT vs. inhibitor-resistant BRISC\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure of inhibited complex with mutagenesis validation and orthogonal cellular assays confirming selectivity and mechanism, single preprint study but rigorous\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"BRCC3 (BRCC36) is a K63-linked polyubiquitin chain-specific deubiquitinase (JAMM/MPN+ zinc metalloprotease) that functions exclusively within two distinct multisubunit complexes: the nuclear BRCA1-A complex (with ABRAXAS as scaffold, also containing RAP80, BRE, NBA1, and BRCA1) that recognizes RNF8/Ubc13-generated K63-ubiquitin marks at DNA double-strand breaks to regulate DSB end resection and BRCA1 localization, and the cytoplasmic BRISC complex (with ABRO1/KIAA0157 as scaffold and SHMT2 as a regulatory adaptor that can inhibit DUB activity) that controls inflammatory signaling by deubiquitinating NLRP3 inflammasome components, IFNAR1, tankyrase 1, and other substrates; BRCC3 DUB activity is allosterically activated by heterodimerization with the pseudo-DUB ABRO1 or ABRAXAS and requires higher-order super-dimer assembly for full activity and substrate targeting.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRCC3 (BRCC36) is a K63-linked polyubiquitin chain-specific deubiquitinase that uses a JAMM/MPN+ zinc metalloprotease mechanism rather than an active-site cysteine, and it cleaves K63 chains exclusively, sparing K6-, K11-, K29-, K48-, and alpha-linked chains [#0]. Its activity is partitioned between two scaffold-defined multisubunit complexes that share the common subunits BRE and NBA1/MERIT40: the nuclear BRCA1-A complex, organized by the ABRAXAS scaffold together with RAP80, BRCA1/BARD1, and BRCC45, and the cytoplasmic BRISC complex, organized by the ABRO1/KIAA0157 scaffold [#1, #3, #4]. BRCC3 is catalytically inert as a homodimer and is allosterically switched to an active conformation by heterodimerization with the pseudo-DUB scaffolds, with a higher-order 'super-dimer' assembly required for full activity and for engaging targeting subunits such as SHMT2 and RAP80; the adaptor subunits diversify substrate targeting, with ABRAXAS providing a high-affinity BRCA1 site and SHMT2 acting as an inhibitory adaptor on BRISC [#8, #11]. In the DNA damage response, the BRCA1-A complex is recruited to double-strand breaks through RAP80 UIM binding to RNF8/Ubc13-generated K63 chains, and BRCC3 hydrolase activity counterbalances RNF8 ligase activity to set steady-state ubiquitin levels, limit DSB end resection, and control BRCA1 focus formation and phosphorylation [#1, #2, #6, #9]. Through the cytoplasmic BRISC complex, BRCC3 controls inflammatory and immune signaling by deubiquitinating NLRP3 to license inflammasome activation and by acting on IFNAR1 and STAT1 to sustain type I interferon antiviral responses [#5, #16, #17, #19]. BRCC3 additionally deubiquitinates and stabilizes a broad set of cell-cycle and signaling substrates including tankyrase 1, ALK2, HMGCR, beta-catenin, and ZEB1, linking it to telomere cohesion, BMP/TGF-beta signaling, vascular calcification, and tumor cell behavior [#10, #21, #20, #23, #29].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that BRCC36 is required for the BRCA1 DNA-damage response, the first cellular function assigned to the protein.\",\n      \"evidence\": \"siRNA knockdown in breast cancer lines with BRCA1/gamma-H2AX foci, phosphorylation, and apoptosis readouts\",\n      \"pmids\": [\"16707425\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define BRCC36 enzymatic activity or substrate\", \"Mechanism of BRCA1 regulation not resolved at molecular level\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined BRCC36 as a subunit of the BRCA1-A complex and mapped how the complex is recruited to DSBs, placing BRCC36 downstream of RNF8/Ubc13 K63 ubiquitin marks.\",\n      \"evidence\": \"Co-IP, coiled-coil domain mapping, and RNAi of RNF8/Ubc13 with foci assays\",\n      \"pmids\": [\"18077395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic role of BRCC36 within the complex not demonstrated\", \"Did not establish linkage specificity of any DUB activity\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified BRCC36 as the catalytic K63-specific JAMM/MPN+ DUB of the BRISC complex and showed it opposes RNF8-driven ubiquitination at DSBs, unifying its enzymatic identity with its DDR role.\",\n      \"evidence\": \"Multistep biochemical fractionation with linkage-specific DUB assays; catalytic-mutant epistasis with RNF8 depletion and IR sensitivity\",\n      \"pmids\": [\"19214193\", \"19202061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of activation not known\", \"Full substrate repertoire at chromatin undefined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed BRCC36 partitions into two scaffold-defined complexes (nuclear ABRAXAS, cytoplasmic KIAA0157/ABRO1) in dynamic balance, explaining how one DUB serves distinct compartments.\",\n      \"evidence\": \"Co-IP, subcellular fractionation, siRNA, and in vitro DUB assay on K63-diUb-H2A substrate\",\n      \"pmids\": [\"20656690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of complex switching not defined\", \"How scaffolds regulate activity unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established BRE and NBA1/MERIT40 as shared subunits whose interaction maintains integrity of both complexes and is required for IR resistance and BRCA1 recruitment.\",\n      \"evidence\": \"Reciprocal Co-IP, domain mapping, clonogenic survival, and immunofluorescence\",\n      \"pmids\": [\"21282113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address cytoplasmic BRISC function\", \"Contribution of these subunits to catalysis unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated an in vivo developmental requirement by showing BRCC3 loss causes angiogenesis defects rescuable by endothelial expression.\",\n      \"evidence\": \"Zebrafish morpholino knockdown with tissue-specific rescue and vascular imaging\",\n      \"pmids\": [\"21596366\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular substrate driving angiogenesis phenotype not identified\", \"Relationship to DUB activity not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified NLRP3 as a BRISC substrate and BRCC3 as a positive regulator of inflammasome activation, opening its inflammatory signaling role.\",\n      \"evidence\": \"Pharmacological DUB inhibition, siRNA, ubiquitination and caspase-1/IL-1beta assays\",\n      \"pmids\": [\"23246432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ubiquitin chains on NLRP3 not fully mapped\", \"Cellular triggers coupling BRISC to NLRP3 not defined here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the structural basis of activation, showing BRCC36 is inactive as a homodimer, activated by heterodimerization with the pseudo-DUB KIAA0157, and requires a super-dimer for full activity and targeting-subunit binding.\",\n      \"evidence\": \"X-ray crystallography, DUB assays, interface mutagenesis, SEC/AUC, and pulldowns\",\n      \"pmids\": [\"26344097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not capture substrate-bound state\", \"Regulation of homodimer-to-heterodimer transition in cells unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Refined the DDR role by showing BRCC36 catalytic activity limits DSB end resection and BRCA1-A accumulation independently of complex integrity, and identified tankyrase 1 as a cell-cycle-regulated BRISC substrate at telomeres.\",\n      \"evidence\": \"RNAi/CRISPR catalytic inactivation with resection assays; Co-IP, cell-cycle-staged ubiquitination, and telomere FISH\",\n      \"pmids\": [\"27288411\", \"27993934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How catalytic activity selectively limits resection mechanistically unclear\", \"Crosstalk between RNF8 and BRISC at telomeres not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided high-resolution structures of both complexes, revealing ABRAXAS sequesters BRCA1 away from DSBs and SHMT2 acts as an inhibitory adaptor on BRISC, explaining adaptor-driven functional diversification.\",\n      \"evidence\": \"Cryo-EM and X-ray crystallography with in vitro DUB and binding assays and mutagenesis\",\n      \"pmids\": [\"31253574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo control of SHMT2 inhibition not defined\", \"Substrate engagement geometry not captured\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked BRCC3 DUB function to leukemia by showing t(8;21) AML mutations abrogate its activity on IFNAR1 and inflammasome function, with loss promoting self-renewal.\",\n      \"evidence\": \"CRISPR inactivation, IFNAR1 DUB activity assays, colony-forming and cytokine readouts\",\n      \"pmids\": [\"31576005\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role in leukemogenesis vs. correlation not fully established\", \"Substrate hierarchy in AML cells unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed BRCC36 is stabilized by ABRO1 competing with the E3 ligase WWP2, and maintains STAT1 noncatalytically via USP13, expanding regulation of and by BRCC36 in antiviral immunity.\",\n      \"evidence\": \"Competition Co-IP, ubiquitination and degradation assays; STAT1 stability and viral challenge in BRCC36-deficient mice\",\n      \"pmids\": [\"33107021\", \"32673428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Noncatalytic scaffolding role mechanistically distinct from DUB activity, not structurally defined\", \"In vivo relevance of WWP2 axis incomplete\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded the substrate and disease landscape by linking BRCC36 to FLT3-ITD K63-ubiquitination in AML and to ICP0-driven degradation of BRCC36 during HSV-1 infection.\",\n      \"evidence\": \"Proximity labeling, K63-ubiquitination and site mutagenesis, STAT5 readouts; viral infection Co-IP with IFNAR1 readout\",\n      \"pmids\": [\"38288901\", \"33857816\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BRCC36 cleaves vs. reads FLT3-ITD ubiquitin not fully resolved\", \"Generality of viral targeting of BRCC36 unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected BRCC3-NLRP3 deubiquitination to a defined upstream pathway (TET2 loss -> JNK1) in clonal-hematopoiesis-accelerated atherosclerosis, with pharmacological and genetic inhibition reversing disease.\",\n      \"evidence\": \"Isogenic TET2-deficient macrophages, NLRP3 ubiquitylation assays, Tet2 CH mouse model, ABRO1 hematopoietic KO, holomycin inhibition\",\n      \"pmids\": [\"37781816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link from JNK1 to BRCC3 activity not fully defined\", \"Human therapeutic translation untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Broadened the catalytic substrate repertoire and disease links by identifying ALK2, HMGCR, beta-catenin, ZEB1, CRBN, and MET as BRCC3 substrates across vascular, metabolic, and cancer contexts.\",\n      \"evidence\": \"Co-IP, K63-specific ubiquitination and site mutagenesis assays, catalytic-mutant controls, reporter assays, and mouse models\",\n      \"pmids\": [\"38557054\", \"38178583\", \"39227917\", \"38449391\", \"39136771\", \"38470543\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Many substrates rest on single-lab Co-IP without structural validation\", \"Whether targeting occurs via BRISC, BRCA1-A, or other assemblies not always defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated selective pharmacological control of BRISC, providing proof-of-concept that BRCC36 can be inhibited within one complex without affecting the other.\",\n      \"evidence\": \"Cryo-EM of molecular-glue-stabilized autoinhibited BRISC dimer, DUB and IFNAR1 ubiquitylation assays, inhibitor-resistant mutant validation (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Peer review pending\", \"Selectivity and efficacy in vivo not yet established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRCC3 substrate selection is governed across its many reported targets — which assembly, adaptor, and targeting subunit route each substrate to the catalytic core in vivo — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying substrate-recruitment model linking the diverse reported substrates\", \"Most newer substrates rest on single-lab Co-IP without reciprocal or structural validation\", \"Catalytic vs. noncatalytic scaffolding contributions not systematically separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 3, 5, 10, 20, 21, 23, 24, 29]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 9, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 5, 10]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [1, 2, 6, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 16, 17, 18, 19]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 3, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [21, 22, 23, 30]}\n    ],\n    \"complexes\": [\"BRCA1-A complex\", \"BRISC complex\"],\n    \"partners\": [\"ABRAXAS\", \"ABRO1\", \"RAP80\", \"BRE\", \"MERIT40\", \"SHMT2\", \"BRCA1\", \"USP13\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}